We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

35 hedge funds and large institutions have $15.6M invested in Immix Biopharma in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

188% more capital invested

Capital invested by funds: $5.43M → $15.6M (+$10.2M)

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

25% more funds holding

Funds holding: 28 → 35 (+7)

15.91% more ownership

Funds ownership: 4.02% → 19.93% (+16%)

Holders
35
Holders Change
+7
Holders Change %
+25%
% of All Funds
0.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
14
Increased
13
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$6.02M
2
BL
Bleichroeder LP
New York
+$3.29M
3
CCC
Cable Car Capital
California
+$2.6M
4
LCM
Lynwood Capital Management
Ontario, Canada
+$1.57M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$710K
2
MAWA
Moss Adams Wealth Advisors
Washington
-$138K
3
JF
Jump Financial
Illinois
-$128K
4
Jane Street
Jane Street
New York
-$103K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$72K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$27.8K +$32.4K +8,361 +1,233%
TRCT
27
Tower Research Capital (TRC)
New York
$17.5K +$19.8K +5,119 +887%
UBS Group
28
UBS Group
Switzerland
$16.1K +$10.2K +2,630 +100%
SPIA
29
Steward Partners Investment Advisory
New York
$4.58K +$5.78K +1,492 New
TIM
30
Tortoise Investment Management
New York
$3.99K – – –
Qube Research & Technologies (QRT)
31
Qube Research & Technologies (QRT)
United Kingdom
$3.82K +$4.81K +1,243 New
Wells Fargo
32
Wells Fargo
California
$1.33K +$167 +43 +11%
Simplex Trading
33
Simplex Trading
Illinois
$1K +$1.97K +509 New
FIA
34
FNY Investment Advisers
New York
$78 +$98.7K +25,500 New
EI
35
EAM Investors
California
– -$710K -102,661 Closed
MAWA
36
Moss Adams Wealth Advisors
Washington
– -$138K -20,000 Closed
JF
37
Jump Financial
Illinois
– -$128K -18,500 Closed
Jane Street
38
Jane Street
New York
– -$103K -14,922 Closed
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
– -$72K -10,000 Closed
Bank of America
40
Bank of America
North Carolina
– -$11K -1,594 Closed
Osaic Holdings
41
Osaic Holdings
Arizona
– -$2.42K -350 Closed
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
– -$240 -62 -91%
1
2

IMMX Hedge Fund Activity: Q1 2024 in Review

35 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2024, worth a combined $15.6M — up 188% from $5.43M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IMMX positions and 7 closed out — a net gain of 7 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $6.02M. The largest seller was EAM Investors, exiting entirely with an estimated $710K sold.

  • 35 institutional investors held Immix Biopharma (IMMX) as of Q1 2024, up from 28 in Q4 2023.
  • Funds reported $15.6M of Immix Biopharma stock for Q1 2024, up 188% quarter-over-quarter.
  • 14 funds opened new Immix Biopharma positions in Q1 2024 and 7 closed out, a net change of +7 holders.
  • The largest Immix Biopharma buyer in Q1 2024 was AIGH Capital Management, an estimated $6.02M added.
  • The largest Immix Biopharma seller in Q1 2024 was EAM Investors, an estimated $710K sold.

Based on aggregated 13F filings for Q1 2024.